MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on innovative cancer therapies, has appointed Eric Risser as its new President and Chief Executive Officer, effective August 13, 2025. Risser, who has been with MacroGenics since 2009, most recently served as Chief Operating Officer. He succeeds Scott Koenig, who steps down after 24 years in the role. Risser brings extensive experience from his previous positions in corporate development at MacroGenics and Johnson & Johnson, as well as roles in investment banking, venture capital, and strategy consulting.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MacroGenics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9511798-en) on August 13, 2025, and is solely responsible for the information contained therein.